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Introduction
Epilepsy remains a significant problem of  public health 
in emerging countries. At least 50 million people in the 
world have epilepsy and approximately 85% of  them live 
in developing countries1,2,3. The high incidence of  epilep-
sy in these countries is often due to parasitic and bacte-
rial infections (such as cysticercosis, toxoplasmosis, hy-
datid cysts, tuberculosis…), perinatal hypoxia due to poor 
conditions for home births and maternal diseases, head 
trauma, toxic agents (including alcohol and drugs), and 
hereditary factors.4,5
Besides the high frequency of  epilepsy, treatment in 
emerging countries is also a problem. A large percentage 
of  the population with epilepsy is not properly treated6.
Compounding this issue, many anti-convulsant drugs 
are also not available. Moreover, these drugs are not af-
fordable for many patients as most people in develop-
ing countries lack health insurance. Surgery, if  indicated, 
is also usually either not available, not accessible or not 
affordable, as it requires important personal expense in 
addition to the travel and accommodation expenses.
The direct costs of  epilepsy are thus important, but indi-
rect costs are also considerable due to loss of  opportuni-
ties and productivity. Therefore, there is a genuine need 
for therapies that would be effective, available and afford-
able for all patients with epilepsy who can’t be adequately 
treated.
The classic ketogenic diet was developed in 1921. It was 
designed originally to mimic the ketotic effect of  fast-
ing, resulting in an anti-epileptic effect, however it likely 
works through effects on mitochondria. The Interna-
tional League against Epilepsy has recently become very 
interested in this therapy as it has gained worldwide at-
tention, including in developing countries7 (www.ilae.
org/Commission/medther/keto-index.cfm). The classic 
ketogenic diet (KD) has been widely used and its effi-
cacy and safety have been demonstrated7. On the other 
hand, there has been a tendency in developing countries 
to use traditional therapies such as plants or special diets. 
There is also a current trend throughout the world of  
using non-pharmacological therapies8,9. Dietary therapies 
would be easily accepted as a non-pharmacological thera-
peutic option with a proved effectiveness and tolerability.
However, the diet can be difficult to adhere to as signifi-
cant amounts of  fats with limited proteins, carbohydrates 
and fluids have to be used. It is not available in many 
countries as it requires traditionally a 3-4 day hospitaliza-
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tion with specialized neurologist and dietitian consulta-
tion. Though the KD is less expensive than many anti-
convulsants, the prices of  foods used are relatively high, 
as even in some developed countries occasional financial 
difficulties with the diet are reported11. On the other 
hand, calculating a 4:1 ratio ketogenic diet is impossible 
for an illiterate patient or care giver.
Recently, less restrictive diets have been developed. 
Among these, the Modified Atkins Diet (MAD) has many 
advantages, primarily that its efficacy appears in studies to 
date to be very similar to the classical KD11,12. In MAD, 
approximately 65% of  calories are from fat sources. It is 
less restrictive, while still requiring decreased intakes of  
carbohydrates but with no protein, calorie, or fluid restric-
tions. Another key difference is that the, MAD does not 
require hospitalization and can be started as an out-pa-
tient without fasting.  The MAD has also been reported 
in two studies to be possible to administer via email to 
patients without even an in-person clinic visit13,14. Anoth-
er point is that the caregiver or the patient in MAD has 
to calculate only carbohydrates that should be less than 
10 grams per day for children and less than 20 grams for 
adults, while the KD, calculation is difficult as proteins, 
fats, carbohydrates and even calories should all be taken 
into account using computer programs. MAD is thus of-
ten easier to start and follow, even if  the person who has 
to prepare the meals has a low level of  education.
This is probably one of  the strongest points of  MAD, as 
the lowest literacy rates are observed in developing coun-
tries.15
Another advantage of  MAD is that it can be easily adapt-
ed to local dishes and traditional recipes. A meditera-
nean diet, especially the Moroccan one for example, uses 
vegetables, eggs, meat, olive and argan oil. A patient on 
MAD would be then able to share the family’s meals, with 
slight modifications, by adding more fat and/or decreas-
ing foods that contain carbohydrates. Dietitian plays an 
important role in adapting the diet to local eating habits 
and finding substitutes to sweet ingredients. Wheat flour, 
for example, can be replaced by hemp flour, almonds or 
sesame in some dishes.
Conclusion and recommendation
For all these reasons, we think that dietary therapies, es-
pecially MAD, should be encouraged as a therapeutic op-
tion in developing countries, not only for drug resistant 
epilepsy, but also potentially as a first line therapy when 
medical or surgical treatment isn’t available or can’t be 
afforded. MAD is probably the most appropriate in this 
specific context as its efficacy is similar to the ketogenic 
diet, but with a better tolerability, ease to use, and less 
costs. Currently, the diet is used worldwide for the treat-
ment of  epilepsy though it was challenging to introduce 
it in some countries, like Asian countries were customary 
diets contain less fat than western diets16. It would be in-
teresting for African practitioners to share their experi-
ence of  MAD and assess, through studies, the efficacy 
and applicability of  the diet on the continent.
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